Tetra Bio-Pharma (TSX:TBP, OTCQB:TBPMF) Inc said it has engaged Christine Caron as a patient partner to actively collaborate in research, knowledge translation, and patient engagement within the pain and sepsis communities.
Caron, who lost multiple limbs after a dog bite sent her into septic shock, will be involved in reviewing and commenting on informed consent forms, questionnaires, or interview guides related to Tetra's clinical trials.
“We are very pleased to have Ms. Caron join the Tetra team as its first Patient Partner,” Tetra Bio-Pharma (TSX:TBP, OTCQB:TBPMF) CEO Guy Chamberland said in a statement.
READ: Tetra Bio-Pharma progressing fast as it advances coronavirus drug candidate ARDS-003 to human trials
“Christine will provide valuable insights about living with post-infection and pain, due to her amputations because of Sepsis, that may validate or change the direction of concepts we explore, such as targeting outcomes that are important to patients,” Chamberland added.
Caron also commented, stating: “I am thrilled to join Tetra in the fight against Sepsis by contributing to advocacy, health literacy, knowledge transfer, and to support families who share this journey. I also believe in the therapeutic benefits of cannabis and will advocate to bring safer pain management prescription alternatives to patients.”
Tetra Bio-Pharma noted that Caron will also be assisting with knowledge translation planning and with sharing Tetra's research results with key audiences, such as the Amputee Coalition of Canada, Sepsis Canada, Global Sepsis Alliance, and Sepsis Alliance.
Ottawa-based Tetra Bio runs a US Food & Drug Administration and a Health Canada-cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.
Contact Sean at sean@proactiveinvestors.com